Scaling opioid overdose prevention and naloxone dispensation among rural and small metro area pharmacists: findings from a qualitative study

References

• Abouk, R., Pacula, R. L., & Powell, D. (2019). Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose. JAMA Internal Medicine, 179(6), 805–811. https://doi.org/10.1001/jamainternmed.2019.0272
   PubMed Web of Science ®Google Scholar
• Bakhireva, L. N., Bautista, A., Cano, S., Shrestha, S., Bachyrycz, A. M., & Cruz, T. H. (2018). Barriers and facilitators to dispensing of intranasal naloxone by pharmacists. Substance Abuse, 39(3), 331–341. https://doi.org/10.1080/08897077.2017.1391924
   PubMed Web of Science ®Google Scholar
• Carpenter, D. M., Dhamanaskar, A. K., Gallegos, K. L., Shepherd, G., Mosley, S. L., & Roberts, C. A. (2019). Factors associated with how often community pharmacists offer and dispense naloxone. Research in Social and Administrative Pharmacy, 15(12), 1415–1418. https://doi.org/10.1016/j.sapharm.2018.07.008
   PubMed Web of Science ®Google Scholar
• Crawford, N. D., Amesty, S., Rivera, A. V., Harripersaud, K., Turner, A., & Fuller, C. M. (2014). Community impact of pharmacy-randomized intervention to improve access to syringes and services for injection drug users. Health Education & Behavior, 41(4), 397–405. https://doi.org/10.1177/1090198114529131
   PubMed Web of Science ®Google Scholar
• CVS Health. By the numbers: How do consumers engage with pharmacists? https://cvshealth.com/thought-leadership/by-the-numbers-how-do-consumers-interact-with-pharmacists#footnote-1. Published March 9th, 2017
   Google Scholar
• Donovan, E., Case, P., Bratberg, J. P., Baird, J., Burstein, D., Walley, A. Y., & Green, T. C. (2019). Beliefs associated with pharmacy-based naloxone: A qualitative study of pharmacy-based naloxone purchasers and people at risk for opioid overdose. Journal of Urban Health, 96(3), 367–378. https://doi.org/10.1007/s11524-019-00349-1
   PubMed Web of Science ®Google Scholar
• Fuller, C. M., Galea, S., Caceres, W., Blaney, S., Sisco, S., & Vlahov, D. (2007). Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. American Journal of Public Health, 97(1), 117–124. https://doi.org/10.2105/AJPH.2005.069591
   PubMed Web of Science ®Google Scholar
• Fuller, C. M., Turner, A. K., Hernández, D., Rivera, A. V., Amesty, S., Lewis, M. D., & Feldman, S. (2013). Attitudes toward Web application supporting pharmacist–clinician comanagement of postexposure prophylaxis patients. Journal of the American Pharmacists Association, 53(6), 632–639. https://doi.org/10.1331/JAPhA.2013.12208
   PubMed Web of Science ®Google Scholar
• Gauthier, T. P., Toro, M., Carrasquillo, M. Z., Corentin, M., & Lichtenberger, P. (2019). A PrEP Model incorporating clinical pharmacist encounters and antimicrobial stewardship program oversight may improve retention in care. Clinical Infectious Diseases, 68(2), 347–349. https://doi.org/10.1093/cid/ciy640
   PubMed Web of Science ®Google Scholar
• Graves, R. L., Andreyeva, E., Perrone, J., Shofer, F., Merchant, R. M., & Meisel, Z. F. (2019). Naloxone availability and pharmacy staff knowledge of standing order for naloxone in Pennsylvania pharmacies. Journal of Addiction Medicine, 13(4), 272. https://doi.org/10.1097/ADM.0000000000000492
   PubMed Web of Science ®Google Scholar
• Green, T. C., Case, P., Fiske, H., Baird, J., Cabral, S., Burstein, D., Schwartz, V., Potter, N., Walley, A. Y., & Bratberg, J. (2017). Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. Journal of the American Pharmacists Association, 57(2), S19–S27. https://doi.org/10.1016/j.japh.2017.01.013
   PubMed Web of Science ®Google Scholar
• Guy, G. P., Jr, Haegerich, T. M., Evans, M. E., Losby, J. L., Young, R., & Jones, C. M. (2019). Vital signs: Pharmacy-based naloxone dispensing—United States, 2012–2018. Morbidity and Mortality Weekly Report, 68(31), 679. https://doi.org/10.15585/mmwr.mm6831e1
   PubMed Web of Science ®Google Scholar
• Lewis, C. F., Rivera, A. V., Crawford, N. D., DeCuir, J., & Amesty, S. (2015). Pharmacy-randomized intervention delivering HIV prevention services during the syringe sale to people who inject drugs in New York City. Drug and Alcohol Dependence, 153(aug1 1), 72–77. https://doi.org/10.1016/j.drugalcdep.2015.06.006
   PubMedGoogle Scholar
• Lieberman, A., & Davis, C. Legal interventions to reduce overdose mortality: Naloxone access laws. Network for Public Health Law. https://www.networkforphl.org/resources/legal-interventions-to-reduce-overdose-mortality-naloxone-access-and-good-samaritan-laws/. Published February 2, 2021
   Google Scholar
• McAuley, A., Munro, A., Bird, S. M., Hutchinson, S. J., Goldberg, D. J., & Taylor, A. (2016). Engagement in a National Naloxone Programme among people who inject drugs. Drug and Alcohol Dependence, 162(may1 1), 236–240. https://doi.org/10.1016/j.drugalcdep.2016.02.031
   PubMedGoogle Scholar
• Monnat, S. M. (2018). Factors associated with county-level differences in US drug-related mortality rates. American Journal of Preventive Medicine, 54(5), 611–619. https://doi.org/10.1016/j.amepre.2018.01.040
   PubMed Web of Science ®Google Scholar
• Morton, K. J., Harrand, B., Floyd, C. C., Schaefer, C., Acosta, J., Logan, B. C., & Clark, K. (2017). Pharmacy-based statewide naloxone distribution: A novel “top-down, bottom-up” approach. Journal of the American Pharmacists Association, 57(2), S99–S106. https://doi.org/10.1016/j.japh.2017.01.017
   PubMed Web of Science ®Google Scholar
• Nielsen, S., Menon, N., Larney, S., Farrell, M., & Degenhardt, L. (2016). Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. Addiction, 111(12), 2177–2186. https://doi.org/10.1111/add.13517
   PubMed Web of Science ®Google Scholar
• Pear, V. A., Ponicki, W. R., Gaidus, A., Keyes, K. M., Martins, S. S., Fink, D. S., Rivera-Aguirre, A., Gruenewald, P. J., & Cerdá, M. (2019). Urban-rural variation in the socioeconomic determinants of opioid overdose. Drug and Alcohol Dependence, 195(2019 Feb 1), 66–73. https://doi.org/10.1016/j.drugalcdep.2018.11.024
   PubMedGoogle Scholar
• Pricolo, A., & Nielsen, S. (2018). Naloxone rescheduling in Australia: Processes, implementation and challenges with supply of naloxone as a ‘pharmacist only’over‐the‐counter medicine. Drug and Alcohol Review, 37(4), 450–453. https://doi.org/10.1111/dar.12547
   PubMed Web of Science ®Google Scholar
• Rudolph, A. E., Standish, K., Amesty, S., Crawford, N. D., Stern, R. J., Badillo, W. E., Boyer, A., Brown, D., Ranger, N., Orduna, J. G., & Lasenburg, L. (2010). A community-based approach to linking injection drug users with needed services through pharmacies: An evaluation of a pilot intervention in New York City. AIDS Education and Prevention, 22(3), 238–251. https://doi.org/10.1521/aeap.2010.22.3.238
   PubMed Web of Science ®Google Scholar
• Ruhm, C. J. (2017). Geographic variation in opioid and heroin involved drug poisoning mortality rates. American Journal of Preventive Medicine, 53(6), 745–753. https://doi.org/10.1016/j.amepre.2017.06.009
   PubMed Web of Science ®Google Scholar
• Smart, R., Geiger, C. K., Jones, C. M., & Stein, B. D. (2020). An observational study of retail pharmacy naloxone prescriptions: Differences across provider specialties and patient populations. Journal of General Internal Medicine, 35(6), 1768–1775. https://doi.org/10.1007/s11606-019-05448-y
   PubMed Web of Science ®Google Scholar
• Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R. (1996). Heroin overdose: The case for take-home naloxone. Bmj, 312(7044), 1435–1436. https://doi.org/10.1136/bmj.312.7044.1435
   PubMedGoogle Scholar
• Tofighi, B., Lekas, H. M., Williams, S. Z., Martino, D., Blau, C., & Lewis, C. F. (2021). Rural and small metro area naloxone-dispensing pharmacists’ attitudes, experiences, and support for a frontline public health pharmacy role to increase naloxone uptake in New York State, 2019. Journal of Substance Abuse Treatment, 129(oct1 1), 108372. https://doi.org/10.1016/j.jsat.2021.108372
   PubMedGoogle Scholar
• Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. Bmj, 346(jan30 5), f174–f174. https://doi.org/10.1136/bmj.f174
   PubMed Web of Science ®Google Scholar
• Xu, J., Davis, C. S., Cruz, M., & Lurie, P. (2018). State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug and Alcohol Dependence, 189(1), 37–41. https://doi.org/10.1016/j.drugalcdep.2018.04.020
   PubMedGoogle Scholar
• Zaller, N. D., Yokell, M. A., Green, T. C., Gaggin, J., & Case, P. (2013). The feasibility of pharmacy-based naloxone distribution interventions: A qualitative study with injection drug users and pharmacy staff in Rhode Island. Substance Use & Misuse, 48(8), 590–599. https://doi.org/10.3109/10826084.2013.793355
   PubMed Web of Science ®Google Scholar